The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
Michael Wang, MD discusses progress in the field of treating mantle cell lymphoma, and the results of the SYMPATICO clinical trial which assessed the efficacy of ibrutinib combined with venetoclax among newly diagnosed patients.
Michael Wang, MD discusses progress in the field of treating mantle cell lymphoma, and the results of the SYMPATICO clinical trial which assessed the efficacy of ibrutinib combined with venetoclax among newly diagnosed patients.
At the 2025 Great Debates in Hematologic Malignancies meeting, Tycel Phillips, MD, debates the benefits of utilizing first-line BTK inhibitors to improve overall survival among certain patients with MCL.
At the 2025 Great Debates in Hematologic Malignancies meeting, Tycel Phillips, MD, debates the benefits of utilizing first-line BTK inhibitors to improve overall survival among certain patients with MCL.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
